Advertisement

Translational Stroke Research

, Volume 10, Issue 3, pp 298–307 | Cite as

Contribution of Apelin-17 to Collateral Circulation Following Cerebral Ischemic Stroke

  • Wan Jiang
  • Wei Hu
  • Li Ye
  • Yanghua Tian
  • Ren Zhao
  • Juan Du
  • Bing ShenEmail author
  • Kai Wang
Original Article

Abstract

Apelin, an essential mediator of homeostasis, is crucially involved in cardiovascular diseases, including ischemic stroke. However, the functional roles of apelin-17 in cerebral collateral circulation and ischemic stroke protection are unknown. Here, we investigated the association between plasma apelin-17 levels and collateral circulation in patients with ischemic stroke and examined the mechanism undergirding the effects of apelin-17 on cerebral artery contraction and ischemic stroke protection in an animal model. Plasma nitric oxide (NO), apelin-17, and apelin-36 levels were assessed by enzyme-linked immunosorbent assays in ischemic stroke patients with good or poor collateral circulation and in healthy participants. Additionally, the effects of apelin-17 on rat basilar artery contractions (in vitro) and cerebral ischemia (in vivo) were determined using vessel tension measurements and nuclear magnetic resonance, respectively. Patients with good collateral circulation had significantly higher plasma apelin-17 and apelin-36 levels than both patients with poor collateral circulation and healthy participants and plasma NO levels significantly higher than those in healthy participants. In vitro, apelin-17 pretreatment markedly attenuated U46619-induced rat basilar artery contractions in an endothelium-dependent manner. Additionally, NO production or guanylyl cyclase inhibitors abolished the apelin-17 effect on U46619-induced vascular contraction. Intravenous pretreatment of rats with apelin-17 markedly reduced cerebral infarct volume at 24 h after middle cerebral artery occlusion. Plasma apelin-17 levels in ischemic stroke patients were positively associated with enhanced collateral circulation, which our animal study data suggested may have resulted from an apelin-17-induced cerebral artery dilation mediated through the NO–cGMP pathway.

Keywords

Stroke Apelin-17 Cerebral collateral circulation Basilar artery Endothelium Nitric oxide Cerebral ischemic protection 

Notes

Acknowledgements

The authors would like to thank Lei Zhan for editing the English text in a draft of this manuscript.

Funding Information

The present study was supported by grants from the National Key Research and Development Program of China (2016YFC1300600); Natural Science Foundation of China (Grant No. 81371284, 81570403, 81600286); Overseas Scholars Start Fund from Department of Human Resources and Social Security of Anhui Province; Outstanding Young Investigator of Anhui Medical University; Anhui Provincial Natural Science Foundation (Grant Nos. 1708085MH187, 1508085QH164).

Compliance with Ethical Standards

Research Involving Animals

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Mokin M, Snyder KV, Siddiqui AH, Levy EI, Hopkins LN. Recent endovascular stroke trials and their impact on stroke systems of care. J Am Coll Cardiol. 2016;67:2645–55.  https://doi.org/10.1016/j.jacc.2015.12.077.CrossRefGoogle Scholar
  2. 2.
    Liebeskind DS. Collateral circulation. Stroke. 2003;34(9):2279–84.  https://doi.org/10.1038/nrneurol.2009.193. CrossRefGoogle Scholar
  3. 3.
    Martinon E, Lefevre PH, Thouant P, Osseby GV, Ricolfi F, Chavent A. Collateral circulation in acute stroke: assessing methods and impact: a literature review. J Neuroradiol. 2014;41:97–107.  https://doi.org/10.1016/j.neurad.2014.02.001.CrossRefGoogle Scholar
  4. 4.
    Liebeskind DS. Stroke: The currency of collateral circulation in acute ischemic stroke. Nat Rev Neurol. 2009;5:645–6.  https://doi.org/10.1038/nrneurol.2009.193.CrossRefGoogle Scholar
  5. 5.
    Liu J, Wang Y, Akamatsu Y, Lee CC, Stetler RA, Lawton MT, et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog Neurobiol. 2014;115:138–56.  https://doi.org/10.1016/j.pneurobio.2013.11.004.CrossRefGoogle Scholar
  6. 6.
    Schramm P, Schellinger PD, Fiebach JB, Heiland S, Jansen O, Knauth M, et al. Comparison of ct and ct angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke. 2002;33:2426–32.  https://doi.org/10.1161/01.STR.0000032244.03134.37.CrossRefGoogle Scholar
  7. 7.
    Fischer U, Arnold M, Nedeltchev K, Brekenfeld C, Ballinari P, Remonda L, et al. Nihss score and arteriographic findings in acute ischemic stroke. Stroke. 2005;36(10):2121–5.  https://doi.org/10.1161/01.STR.0000182099.04994.fc.CrossRefGoogle Scholar
  8. 8.
    Muir KW. Stroke in 2015: the year of endovascular treatment. Lancet Neurol. 2016;15:2–3.CrossRefGoogle Scholar
  9. 9.
    Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human apj receptor. Biochem Biophys Res Commun. 1998;251(2):471–6.  https://doi.org/10.1006/bbrc.1998.9489.CrossRefGoogle Scholar
  10. 10.
    Than A, He HL, Chua SH, Xu D, Sun L, Leow MK, et al. Apelin enhances brown adipogenesis and browning of white adipocytes. J Biol Chem. 2015;290(23):14679–91.  https://doi.org/10.1074/jbc.M115.643817.CrossRefGoogle Scholar
  11. 11.
    Yang Y, Lv SY, Ye W, Zhang L. Apelin/apj system and cancer. Clin Chim Acta. 2016;457:112–6.  https://doi.org/10.1016/j.cca.2016.04.001.CrossRefGoogle Scholar
  12. 12.
    Wang C, Wen J, Zhou Y, Li L, Cui X, Wang J, et al. Apelin induces vascular smooth muscle cells migration via a pi3k/akt/foxo3a/mmp-2 pathway. Int J Biochem Cell Biol. 2015;69:173–82.  https://doi.org/10.1016/j.biocel.2015.10.015.CrossRefGoogle Scholar
  13. 13.
    Chapman NA, Dupre DJ, Rainey JK. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class a gpcr. Biochem Cell Biol. 2014;92(6):431–40.  https://doi.org/10.1139/bcb-2014-0072.CrossRefGoogle Scholar
  14. 14.
    Wang W, McKinnie SM, Farhan M, Paul M, McDonald T, McLean B, et al. Angiotensin-converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: physiological effects in the cardiovascular system. Hypertension. 2016;68:365–77.  https://doi.org/10.1161/HYPERTENSIONAHA.115.06892.CrossRefGoogle Scholar
  15. 15.
    Yu XH, Tang ZB, Liu LJ, Qian H, Tang SL, Zhang DW, et al. Apelin and its receptor apj in cardiovascular diseases. Clin Chim Acta. 2014;428:1–8.  https://doi.org/10.1016/j.cca.2013.09.001. CrossRefGoogle Scholar
  16. 16.
    Zhong JC, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res. 2007;74(3):388–95.  https://doi.org/10.1016/j.cardiores.2007.02.002.CrossRefGoogle Scholar
  17. 17.
    Pisarenko OI, Lankin VZ, Konovalova GG, Serebryakova LI, Shulzhenko VS, Timoshin AA, et al. Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion. Mol Cell Biochem. 2014;391(1–2):241–50.  https://doi.org/10.1007/s11010-014-2008-4.CrossRefGoogle Scholar
  18. 18.
    Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110(11 suppl 1):II187–93. doi: https://doi.org/10.1161/01.CIR.0000138382.57325.5c, II-187, II-193.
  19. 19.
    Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99(2):87–92.  https://doi.org/10.1016/S0167-0115(01)00236-1.CrossRefGoogle Scholar
  20. 20.
    Kuklinska AM, Sobkowicz B, Sawicki R, Musial WJ, Waszkiewicz E, Bolinska S, et al. Apelin: a novel marker for the patients with first st-elevation myocardial infarction. Heart Vessel. 2010;25:363–7.  https://doi.org/10.1007/s00380-009-1217-3.CrossRefGoogle Scholar
  21. 21.
    Yang Y, Zhang XJ, Li LT, Cui HY, Zhang C, Zhu CH, et al. Apelin-13 protects against apoptosis by activating amp-activated protein kinase pathway in ischemia stroke. Peptides. 2016;75:96–100.  https://doi.org/10.1016/j.peptides.2015.11.002.CrossRefGoogle Scholar
  22. 22.
    Xin Q, Cheng B, Pan Y, Liu H, Yang C, Chen J, et al. Neuroprotective effects of apelin-13 on experimental ischemic stroke through suppression of inflammation. Peptides. 2015;63:55–62.  https://doi.org/10.1016/j.peptides.2014.09.016.CrossRefGoogle Scholar
  23. 23.
    Gu Q, Zhai L, Feng X, Chen J, Miao Z, Ren L, et al. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the pi3k/akt pathway. Neurochem Int. 2013;63(6):535–40.  https://doi.org/10.1016/j.neuint.2013.09.017.CrossRefGoogle Scholar
  24. 24.
    Hu W, Jiang W, Ye L, Tian Y, Shen B, Wang K. Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases. Sci Rep. 2017;7:5452.  https://doi.org/10.1038/s41598-017-05664-8.CrossRefGoogle Scholar
  25. 25.
    Zhao R, Zhou M, Li J, Wang X, Su K, Hu J, et al. Increased trpp2 expression in vascular smooth muscle cells from high-salt intake hypertensive rats: the crucial role in vascular dysfunction. Mol Nutr Food Res. 2015;59(2):365–72.  https://doi.org/10.1002/mnfr.201400465.CrossRefGoogle Scholar
  26. 26.
    Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91.  https://doi.org/10.1161/01.STR.20.1.84.CrossRefGoogle Scholar
  27. 27.
    Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, et al. Apelin activates l-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides. 2007;28(10):2023–9.  https://doi.org/10.1016/j.peptides.2007.07.016.CrossRefGoogle Scholar
  28. 28.
    Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009;54:598–604.  https://doi.org/10.1161/HYPERTENSIONAHA.109.134619.CrossRefGoogle Scholar
  29. 29.
    Zhang YH. Nitric oxide signalling and neuronal nitric oxide synthase in the heart under stress. F1000Research 2017; 6:742. doi: https://doi.org/10.12688/f1000research.10128.1.
  30. 30.
    Lv D, Li H, Chen L. Apelin and apj, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin Shanghai. 2013;45(7):527–33.  https://doi.org/10.1093/abbs/gmt040.CrossRefGoogle Scholar
  31. 31.
    Yang Y, Zhang X, Cui H, Zhang C, Zhu C, Li L. Apelin-13 protects the brain against ischemia/reperfusion injury through activating pi3k/akt and erk1/2 signaling pathways. Neurosci Lett. 2014;568:44–9.  https://doi.org/10.1016/j.neulet.2014.03.037.CrossRefGoogle Scholar
  32. 32.
    Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52(11):908–13.  https://doi.org/10.1016/j.jacc.2008.06.013.CrossRefGoogle Scholar
  33. 33.
    Palmi M, Meini A. Role of the nitric oxide/cyclic gmp/ca2+ signaling pathway in the pyrogenic effect of interleukin-1beta. Mol Neurobiol. 2002;25(2):133–47.  https://doi.org/10.1385/MN:25:2:133. CrossRefGoogle Scholar
  34. 34.
    Vandael DH, Mahapatra S, Calorio C, Marcantoni A, Carbone E. Cav1.3 and cav1.2 channels of adrenal chromaffin cells: emerging views on camp/cgmp-mediated phosphorylation and role in pacemaking. Biochim Biophys Acta. 2013;1828(7):1608–18.  https://doi.org/10.1016/j.bbamem.2012.11.013.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Wan Jiang
    • 1
    • 2
    • 3
  • Wei Hu
    • 4
  • Li Ye
    • 1
    • 2
    • 3
  • Yanghua Tian
    • 1
    • 2
    • 3
  • Ren Zhao
    • 5
  • Juan Du
    • 6
  • Bing Shen
    • 6
    Email author
  • Kai Wang
    • 1
    • 2
    • 3
  1. 1.Department of NeurologyThe First Affiliated Hospital of Anhui Medical UniversityHefeiChina
  2. 2.Anhui Province Key Laboratory of Cognition and Neuropsychiatric DisordersHefeiChina
  3. 3.Collaborative Innovation Centre of Neuropsychiatric Disorder and Mental HealthHefeiChina
  4. 4.Department of NeurologyAffiliated Provincial Hospital of Anhui Medical UniversityHefeiChina
  5. 5.Department of CardiologyThe First Affiliated Hospital of Anhui Medical UniversityHefeiChina
  6. 6.School of Basic Medical SciencesAnhui Medical UniversityHefeiChina

Personalised recommendations